AlphaHelix is a leading brand in the field of molecular diagnostics, providing state-of-the-art technologies and commercializing new clinical diagnostics. Our mission at AlphaHelix is to design, develop, and distribute products for both the Nordic and international markets. Through close collaboration with leading research groups, we are able to identify new trends in diagnostics early on, fostering partnerships and facilitating product development.

Our patented PCR technology offers faster qPCR/PCR analysis for sample volumes of up to 20 μl. Additionally, our unique method for processing samples enables the detection of viruses and bacteria without time-consuming preparation in just 30 minutes. AlphaHelix Molecular Diagnostics, our parent company, holds patents for fast PCR technology and rapid and reliable detection of 22q11.

2 deletion syndrome, the most common cause of Congenital Heart Defects in fetuses. We trade on the Spotlight Stockmarket and currently have two active subsidiaries: CyberGene, a pioneer in QF-PCR based prenatal diagnostics and male infertility, and Techtum, a provider of clinical diagnostics and research products in the Nordic region since 1975. At Techtum, we specialize in molecular diagnostics of viruses and bacteria, qPCR/PCR/NGS, DNA/RNA extraction, automatic liquid handling equipment, biobank products, and BugScreener™, a system for screening MRSA and other intestinal pathogens.

With our headquarters in Stockholm, Sweden, and offices in Umeå and Helsingborg, we are well-positioned to serve our customers' needs. Contact us today at AlphaHelix to learn more about our innovative products and services